ORIC
ORIC Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
7.52 / 10
Outperform
Analyst sentiment is bullish, with 75% Strong‑Buy and 25% Buy recommendations; key analysts cite solid performance. Fund‑flow is good (7.63/10), showing positive small/medium inflows but negative large/block trends, yielding a mixed but overall favorable capital picture.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
75%
Buy
25%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-24
InstitutionWedbush
Times predicted3
Historical Win Rate33.3%
What is the analyst consensus for ORIC?
- ORIC holds a Bullish analyst rating, with 75% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.52/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
